Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 1, 2013, Pages 1-6

  Paulu, Petra ^a   Osmancik, Pavel ^a   Tousek, Petr ^a   Minarik, Marek ^b   Benesova, Lucie ^b   Motovska, Zuzana ^a   Bednar, Frantisek ^a   Kocka, Viktor ^a   Widimsky, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Genomac Research Institute   (Czech Republic)

Author keywords

Clopidogrel efficacy; Dual antiplatelet therapy; Prognosis; VerifyNow

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; CYTOCHROME P450 2C19; DNA; EPTIFIBATIDE; HEPARIN;

ACUTE CORONARY SYNDROME; AGED; ALLELE; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD SAMPLING; BODY MASS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CYP2C19 GENE; DEATH; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; STABLE ANGINA PECTORIS; THROMBOSIS; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; STROKE; SURVIVAL RATE; TICLOPIDINE;

EID: 84879240884     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0813-8     Document Type: Article

References (22)

1. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 316(7141):1337-1343
2. Antiplatelet Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324:71-86
3. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 345:494-502
5. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE Study. Lancet 358:527-533
6. Wang TH, Bhatt DL, Topol E (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647-654
7. Michelson AD (2004) Platelet function testing in cardiovascular diseases. Circulation 110:e489-e493
8. Gachet Ch, Aleil B (2008) Testing antiplatelet therapy. Eur Heart J Suppl 10:A28-A134
9. Ang L, Mahmud E (2008) Monitoring oral antiplatelet therapy: is it justified? Ther Adv Cardiovasc Dis 2:485-496
10. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow up. Circulation 119:237-242
11. Price MJ, Endemann S, Gollapudi R, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992-1000
12. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 52:1128-1133
13. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJA (2012) Randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 59(24):2159-2164
14. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ (2011) Standard- vs high dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097-1105
15. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474-2483
16. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362
17. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D (2011) Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343:d4588
18. Minarik M, Kopeckova M, Gassman M, Osmancik P, Benesova L (2012) Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing onchip capillary electrophoresis. Electrophoresis 33(8):1306-1310
19. Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T, Horváth IG, Serebruany VL (2010) Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160(3):543-551
20. Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R (2011) Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 24(6):529-534
21. Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R (2007) Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99:1518-1522
22. Wood S ADAPT-DES: Platelet tests predict stent thrombosis for populations, not individuals. Nov 9, 2011. http://www.theheart.org/article/ 1306563.do Accessed 15 Jul 2012